Evidence map›Paper›PMID 25866630›Full record

ArticleImmunity, inflammation and disease2014

Chaperoned amyloid proteins for immune manipulation: α-Synuclein/Hsp70 shifts immunity toward a modulatory phenotype.

Adahir Labrador-Garrido, Marta Cejudo-Guillén, Rebecca Klippstein, Erwin J De Genst, Laura Tomas-Gallardo, María M Leal, Javier Villadiego, Juan J Toledo-Aral, Christopher M Dobson, David Pozo and 1 more

Open access · goldAbstract read
In one paragraph

Article in Immunity, inflammation and disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Immune tolerance therapies for autoimmune diseases based on heat shock protein T-cell epitopes.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Adahir Labrador-GarridoCABIMER, Andalusian Center for Molecular Biology and Regenerative Medicine Seville, Spain ; Department of Medical Biochemistry Molecular Biology and Immunology School of Medicine, University of Seville Spain.
Marta Cejudo-GuillénCABIMER, Andalusian Center for Molecular Biology and Regenerative Medicine Seville, Spain ; Department of Medical Biochemistry Molecular Biology and Immunology School of Medicine, University of Seville Spain.
Rebecca KlippsteinCABIMER, Andalusian Center for Molecular Biology and Regenerative Medicine Seville, Spain ; Department of Medical Biochemistry Molecular Biology and Immunology School of Medicine, University of Seville Spain.
Erwin J De GenstDepartment of Chemistry, University of Cambridge UK.
Laura Tomas-GallardoCABD, Andalusian Center for Developmental Biology Seville, Spain.
María M LealCABIMER, Andalusian Center for Molecular Biology and Regenerative Medicine Seville, Spain.
Javier VilladiegoIBiS Institute of Biomedicine of Seville, University Hospital Virgen del Rocío-CSIC-University of Seville Spain ; Department of Medical Physiology and Biophysics School of Medicine, University of Seville Spain ; CIBERNED, Centers for Networked Biomedical Research in Neurodegenerative Diseases Spain.
Juan J Toledo-AralIBiS Institute of Biomedicine of Seville, University Hospital Virgen del Rocío-CSIC-University of Seville Spain ; Department of Medical Physiology and Biophysics School of Medicine, University of Seville Spain ; CIBERNED, Centers for Networked Biomedical Research in Neurodegenerative Diseases Spain.
Christopher M DobsonDepartment of Chemistry, University of Cambridge UK.
David PozoCABIMER, Andalusian Center for Molecular Biology and Regenerative Medicine Seville, Spain ; Department of Medical Biochemistry Molecular Biology and Immunology School of Medicine, University of Seville Spain.
Cintia RoodveldtCABIMER, Andalusian Center for Molecular Biology and Regenerative Medicine Seville, Spain.
Universidad de Sevilla · ESCentro Andaluz de Biología Molecular y Medicina Regenerativa · ESUniversity of Cambridge · GBAndalusian Health Service · ESInstituto de Biomedicina de Sevilla · ES

Funding

Biotechnology and Biological Sciences Research Council BB/H003843/1Medical Research Council G1002272Wellcome Trust
6 · The paper itself

Abstract

α-Synuclein (αSyn) is a 140-residue amyloid-forming protein whose aggregation is linked to Parkinson's disease (PD). It has also been found to play a critical role in the immune imbalance that accompanies disease progression, a characteristic that has prompted the search for an effective αSyn-based immunotherapy. In this study, we have simultaneously exploited two important features of certain heat-shock proteins (HSPs): their classical "chaperone" activities and their recently discovered and diverse "immunoactive" properties. In particular, we have explored the immune response elicited by immunization of C57BL/6 mice with an αSyn/Hsp70 protein combination in the absence of added adjuvant. Our results show differential effects for mice immunized with the αSyn/Hsp70 complex, including a restrained αSyn-specific (IgM and IgG) humoral response as well as minimized alterations in the Treg (CD4(+)CD25(+)Foxp3(+)) and Teff (CD4(+)Foxp3(-)) cell populations, as opposed to significant changes in mice immunized with αSyn and Hsp70 alone. Furthermore, in vitro-stimulated splenocytes from immunized mice showed the lowest relative response against αSyn challenge for the "αSyn/Hsp70" experimental group as measured by IFN-γ and IL-17 secretion, and higher IL-10 levels when stimulated with LPS. Finally, serum levels of Th1-cytokine IFN-γ and immunomodulatory IL-10 indicated a unique shift toward an immunomodulatory/immunoprotective phenotype in mice immunized with the αSyn/Hsp70 complex. Overall, we propose the use of functional "HSP-chaperoned amyloid/aggregating proteins" generated with appropriate HSP-substrate protein combinations, such as the αSyn/Hsp70 complex, as a novel strategy for immune-based intervention against synucleinopathies and other amyloid or "misfolding" neurodegenerative disorders.

Indexed as

amyloid diseaseheat-shock proteins (HSPs)immunizationimmunomodulationα-synuclein

Identifiers

PMID25866630
PMCPMC4386917
OpenAlexW1498146736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.